ANTENGENE-B(06996): XEVIO approved in Malaysia for a new indication in the treatment of diffuse large B-cell lymphoma.
Dexy Biomedical-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for Xyvio (selinexor), approving Xyvio for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy and are not eligible for autologous stem cell transplantation.
ANTENGENE-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for XEVIOUS (selinexor) to be marketed. XEVIOUS has been approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy and are not eligible for autologous stem cell transplant.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
